Business
HLS Announces Reimbursement for Vascepa® under Alberta's Provincial Drug Plan
HLS Announces Reimbursement for Vascepa® under Alberta's Provincial Drug Plan Cana...
About this update from Hls Therapeutics, Inc.
[{"type":"text","content":"\n\n\n\n HLS Announces Reimbursement for Vascepa® under Alberta's Provincial Drug Plan\n \n\n /* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n \n\n\n\n\n\n Canada NewsWire\n \n\n\n\n\n\n\n With the addition of\n \n Alberta's\n \n public plan, Vascepa will be available to more than 90% of Canadians who are eligible and covered by a public or private plan.\n \n\n\n\n\n\n\n TORONTO\n \n\n ,\n \n\n July 29, 2024\n \n\n /CNW/ - HLS Therapeutics Inc. (\"HLS\" or the \"Company\") (TSX: HLS), a pharmaceutical company focusing on addressing unmet needs in the treatment of psychiatric disorders and cardiovascular disease, announces that it has entered into a Product Listing Agreement (\"PLA\") with the province of\n \n Alberta\n \n , for the listing and public reimbursement of Vascepa (icosapent ethyl). The PLA with Alberta Health is effective\n \n August 1, 2024\n \n .\n \n\n Under the terms of the PLA, Vascepa will be reimbursed as a Special Authority product by Alberta Health for the secondary prevention of cardiovascular events (cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization or hospitalization for unstable angina) in statin-treated patients with established cardiovascular disease and elevated triglycerides.\n \n\n \"The PLA with Alberta Health will significantly improve access and reimbursement for Vascepa in\n \n Canada's\n \n fourth largest province,\" said\n \n Craig Millian\n \n , CEO of HLS. \"Cardiovascular disease remains one of the leading causes of death in\n \n Canada\n \n\n 1\n \n , so we are very pleased to now provide national coverage for Vascepa to more than 90% of eligible Canadians covered by both public and private plans.\"\n \n\n Approximately 12% of all Canadians live in\n \n Alberta\n \n\n 2\n \n . As disclosed previously, HLS has achieved public reimbursement for\n \n Ontario\n \n ,\n \n Quebec\n \n ,\n \n British Columbia\n \n ,\n \n Saskatchewan\n \n ,\n \n New Brunswick\n \n ,\n \n Northwest Territories\n \n , Veterans Affairs and the NIHB program for First Nations and Inuit peoples.\n \n\n\n ABOUT VASCEP...